{"id":"NCT01728805","sponsor":"Kyowa Kirin, Inc.","briefTitle":"Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL","officialTitle":"Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2017-03","completion":"2021-02-17","firstPosted":"2012-11-20","resultsPosted":"2019-04-11","lastUpdate":"2024-04-25"},"enrollment":372,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cutaneous T-Cell Lymphoma"],"interventions":[{"type":"BIOLOGICAL","name":"KW-0761","otherNames":["mogamulizumab","POTELIGEO®"]},{"type":"DRUG","name":"Vorinostat","otherNames":["400 mg orally daily","ZOLINZA®"]}],"arms":[{"label":"KW-0761","type":"EXPERIMENTAL"},{"label":"Vorinostat","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.","primaryOutcome":{"measure":"Progression Free Survival","timeFrame":"From date of randomization at every visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months","effectByArm":[{"arm":"KW-0761","deltaMin":55.3,"sd":null},{"arm":"Vorinostat","deltaMin":28.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":12},"locations":{"siteCount":73,"countries":["United States","Australia","Denmark","France","Germany","Italy","Japan","Netherlands","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["39315857","30100375"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":69,"n":184},"commonTop":["Diarrhoea","Fatigue","Nausea","Infusion Related Reaction","Thrombocytopenia"]}}